Recursion and Genentech announced plans to co-develop a neuroscience small-molecule program after Genentech exercised the first validated target option from their AI-discovery collaboration. Acceptance of the validation package triggers a $3 million milestone payment to Recursion and marks continued value capture from the 2021 deal. The companies declined to disclose the target identity or indications. Recursion says it took about 15 months from target validation initiation to delivery of the validation package, with Genentech planning to use Recursion’s platform across dozens of programs spanning neuroscience and an undisclosed GI-oncology indication. The announcement matters for the AI-drug-discovery sector because it demonstrates the partnership’s internal validation path producing “co-developable” targets, moving beyond discovery-only engagement.